Infliximab reverses inflammatory muscle wasting (sarcopenia) in Crohn's disease
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Summary: Background: Muscle wasting or sarcopenia arising from chronic inflammation is found in 60% of patients with Crohn's disease. Transcriptional protein NF‐κB reduces muscle formation through MyoD transcription and increases muscle breakdown by proteolysis. Aim: As TNF is a potent activator of NF‐κB, and anti‐TNF agent infliximab (IFX) prevents NF‐κB activation, to determine whether or not Crohn's patients treated with IFX gain muscle volume and strength. Methods: We performed a prospective, repeated‐measures cohort study in adult Crohn's disease patients with an acute disease flare. Patients were instructed not to vary diet or activity. Concomitant medications were kept stable. At week 1 (pre‐treatment), week 16 (post‐IFX induction) and week 25 (post‐first IFX maintenance dose), we assessed (i) MRI volume of quadriceps femoris at anatomical mid‐thigh; (ii) maximal concentric quadriceps contractions strength at three specific speeds of contraction; (iii) physical activity by validated instrument (IPAQ); (iv) Three‐day food record of intake and composition (food‐weighing method); (v) Serum levels of IL 6. Results: Nineteen patients (58% female; mean age 33.2 ± 10.7 years) were recruited. IFX increased muscle volume in both legs from baseline (right, 1505 cm 3) to week 25 (right, 1569 cm 3; P = 0.010). IFX also increased muscle strength in both legs from baseline (right 30°/s, 184.8 Nm) to week 25 (right 30°/s, 213.6 Nm; P = 0.002). Muscle volume gain correlated with male gender (P = 0.003). Significant gains in muscle volume and strength were unrelated to prednisolone use. Serum IL 6 levels decreased by week 25 (P = 0.037). Conclusion: The anti‐TNF agent infliximab reverses inflammatory sarcopenia in patients with Crohn's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International physical activity questionnaire: 12-country reliability and validity
CRAIG, C. L., MARSHALL, A. L., SJ??STR??M, M., BAUMAN, A. E., BOOTH, M. L., AINSWORTH, B. E., PRATT, M., EKELUND, U., YNGVE, A., SALLIS, J. F., et al. (2003) · Medicine & Science in Sports & Exercise · doi:10.1249/01.mss.0000078924.61453.fb · Cited by 21,619
Bodine, S. C., Stitt, T. N., Gonzalez, M., Kline, W. O., Stover, G. L., Bauerlein, R., Zlotchenko, E., Scrimgeour, A., Lawrence, J. C., Glass, D. J., et al. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-1014 · Cited by 2,752
IKKβ/NF-κB Activation Causes Severe Muscle Wasting in Mice
Cai, D., Frantz, J. D., Tawa, N. E., Melendez, P. A., Oh, B.-C., Lidov, H. G. W., Hasselgren, P.-O., Frontera, W. R., Lee, J., Glass, D. J., et al. (2004) · Cell · doi:10.1016/j.cell.2004.09.027 · Cited by 1,367
Skeletal Muscle Cutpoints Associated with Elevated Physical Disability Risk in Older Men and Women
Janssen, I. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh058 · Cited by 1,190
Total-body skeletal muscle mass: Estimation by a new dual-energy X-ray absorptiometry method
Kim, J., Wang, Z., Heymsfield, S. B., Baumgartner, R. N., & Gallagher, D. (2002) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/76.2.378 · Cited by 737
Mechanisms of glucocorticoid-induced myopathy
Schakman, O., Gilson, H., & Thissen, J. P. (2008) · Journal of Endocrinology · doi:10.1677/joe-07-0606 · Cited by 521
Mijnarends, D. M., Meijers, J. M. M., Halfens, R. J. G., ter Borg, S., Luiking, Y. C., Verlaan, S., Schoberer, D., Cruz Jentoft, A. J., van Loon, L. J. C., & Schols, J. M. G. A. (2013) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2012.10.009 · Cited by 475
Visser, M., & Schaap, L. A. (2011) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2011.03.006 · Cited by 320
Ivey, F. M., Roth, S. M., Ferrell, R. E., Tracy, B. L., Lemmer, J. T., Hurlbut, D. E., Martel, G. F., Siegel, E. L., Fozard, J. L., Metter, E. J., et al. (2000) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/55.11.m641 · Cited by 288 · cited 1×
“This observation is consistent with a previous finding that men increased their muscle volume about twice as much in response to strength training as did women and experienced greater losses in response to detraining than women.(28) One possible explanation of lower muscle mass in CD patients is poor nutritional statu…”
ResultThe meaning and measurement of lean body mass
Roubenoff, R., & Kehayias, J. J. (2009) · Nutrition Reviews · doi:10.1111/j.1753-4887.1991.tb03013.x · Cited by 218
Cited by
Inflammation and Skeletal Muscle Wasting During Cachexia
Webster, J. M., Kempen, L. J. A. P., Hardy, R. S., & Langen, R. C. J. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.597675 · Cited by 372
“In addition, exacerbations in conditions like RA, COPD, and Crohn’s disease activity may be associated with transient increases in systemic inflammation, followed by sustained loss of body and muscle mass, which are not recovered as a result of other disease-related impairments in, e.g., inactivity, hypoxemia, or maln…”
BackgroundInfluentialCytokine Signaling in Skeletal Muscle Wasting
Zhou, J., Liu, B., Liang, C., Li, Y., & Song, Y.-H. (2016) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.03.002 · Cited by 172
“The TNF chimeric monoclonal antibody infliximab, an agent that blocks TNF-/ action, can increase muscle strength and volume in patients with Crohn's disease [13], and long-term treatment with etanercept, another TNF-/ inhibitor, results in body weight gain in rheumatoid arthritis (RA) patients [14].”
BackgroundPharmacological blockade of TNFα prevents sarcopenia and prolongs survival in aging mice
Sciorati, C., Gamberale, R., Monno, A., Citterio, L., Lanzani, C., De Lorenzo, R., Ramirez, G. A., Esposito, A., Manunta, P., Manfredi, A. A., et al. (2020) · Aging · doi:10.18632/aging.202200 · Cited by 79
“AntiTNFα antibodies might also control muscle loss in chronic diseases such as Crohn's disease and rheumatic diseases [30, 31].”
BackgroundKim, Y., Kim, C.-S., Joe, Y., Chung, H. T., Ha, T. Y., & Yu, R. (2018) · Journal of Medicinal Food · doi:10.1089/jmf.2017.4108 · Cited by 69
Tidball, J. G., Flores, I., Welc, S. S., Wehling-Henricks, M., & Ochi, E. (2021) · Experimental Gerontology · doi:10.1016/j.exger.2020.111200 · Cited by 66
Metadata
- Authors
- Subramaniam, K., Fallon, K., Ruut, T., Lane, D., McKay, R., Shadbolt, B., Ang, S., Cook, M., Platten, J., Pavli, P., & Taupin, D.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2015-01-08
- Volume
- 41
- Issue
- 5
- Pages
- 419-428
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2048549581
- Cited by
- 145
- References
- 12
- FWCI
- 7.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Infliximab reverses inflammatory muscle wasting (sarcopenia) in Crohn's disease. https://app.cochat.ai/papers/10.1111/apt.13058
- The paper
- Subramaniam, K., Fallon, K., Ruut, T., Lane, D., McKay, R., Shadbolt, B., Ang, S., Cook, M., Platten, J., Pavli, P., & Taupin, D. (2015). Infliximab reverses inflammatory muscle wasting (sarcopenia) in Crohn's disease. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.13058
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.